This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

AboutAbout  CRESEMBA®Invasive fungal infections and risk factorsMeet CRESEMBA ®CRESEMBA® patient profilesVirtual Patient ExperienceEfficacyEfficacyInvasive AspergillosisMucormycosis

Menu

Close

LabelDosingDosingDosingSafety ProfileSafety & TolerabilitySafety ProfileEmerging PopulationsEmerging PopulationsICUInvasive fungal infections in the ICUInvasive fungal infections and influenza

Invasive fungal infections in solid organ transplant recipients

Invasive fungal infections and chronic obstructive pulmonary disease

Invasive fungal infections and COVID-19 (CAPA/CAM)
Support & ResourcesResourcesKOL VideosNational/Regional GuidelinesECIL-6 Guidelines
ESCMID
ID Society of America
Videos
Materials
Support & Resources

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

Simple and reliable dosing1Formulations and strength1

The oral and IV dosage of CRESEMBA® is fixed and simple, with a once-daily maintenance regimen and no need to adjust by weight.1

With high oral bioavailability (98%), the IV and oral formulations can be used interchangeably,1 which can help facilitate the switch from hospital to home care.

Simple and interchangeable IV and oral dosing¹

For long-term treatment beyond 6 months, the benefit-risk balance should be carefully considered.

Linear and predictable PK

CRESEMBA® has a linear PK profile up to 600 mg/day, with low inter-patient and intra-patient variability.1-4

TDM is not routinely recommended for CRESEMBA®.1,4,5 Management should be directed in accordance with local Trust policy.

CRESEMBA® can be taken with or without food.1,6

Dose adjustments1

No dose adjustment is necessary with CRESEMBA® for:

a. CRESEMBA® has not been studied in patients with severe hepatic impairment (Child-Pugh Class C); use in these patients is not recommended unless the potential benefit outweighs the risks. These patients should be carefully monitored for potential drug toxicity.1

Fewer and more manageable drug-drug interactions than other azoles1,7–9

CRESEMBA® interacts with selected CYP450 isoenzymes to a lesser degree than other azoles.1,3 

Dose adjustments are not required for CRESEMBA® in combination with several commonly used medications.1 

Unlike other azoles, CRESEMBA® can also be used with ibrutinib, and coadministration appears to be well tolerated.10,11

Scroll left to view table
Recommendations for the coadministration of CRESEMBA® with key medications1,b
Concomitant medication
  • Proton pump inhibitors
 
  • Statins
 
  • Warfarin
 
  • Methotrexate
 
  • Repaglinide
  • Immunosuppressants (tacrolimus, sirolimus and ciclosprorin only)
 
  • Short-acting opiates (alfentanyl and fentanyl)
 
  • Digoxin
 
  • Anticancer agents (other than methotrexate) including ibrutinib11
 
  • Antiretrovirals (other than high-dose ritonavir, efavirenz and etravirine)
   
  • Dabigatran etexilate
 
  • Midazolam
 
  • Colchicine
Recommendation No dose adjustment for either CRESEMBA® or the concomitant medication Monitoring of concomitant medication and dose adjustment if required
Please refer to the CRESEMBA® Summary of Product Characteristics for full list of drug interactions and recommendations concerning coadministration.

b. CRESEMBA® is contraindicated in coadministration with ketoconazole, high-dose ritonavir, and strong CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates, phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine.1 Coadministration with prednisolone, aprepitant, pioglitazone, should be avoided unless the potential benefit outweighs the risk. For further details and a full list of drug interactions, please consult the Summary of Product Characteristics.

CRESEMBA® IV does not contain sucrose, can be diluted with saline or dextrose, and can be used with common anti-diabetes therapies such as metformin (metformin dose reduction may be required) and repaglinide.1

CRESEMBA® offers a simple dosing regimen with lower potential for drug interactions than other azoles,1,7–9 giving you the flexibility you need for complex clinical scenarios

How do invasive fungal infections impact your critically ill patients in the ICU?
Find out more Loading
Learn more about the economic value of CRESEMBA®
Watch nowLoading

BTK, Bruton’s tyrosine kinase; IV, intravenous; PK, pharmacokinetics; TDM, therapeutic drug monitoring

Prescribing Information:

Click here for CRESEMBA® (isavuconazole) and Vfend (voriconazole) prescribing information

References:1. CRESEMBA GB Summary of Product Characteristics.
2. Kaindl T et al. J Antimicrob Chemother 2019;74(3):761–767.
3. Natesan SK and Chandrasekar PH. Infect Drug Resist 2016;9:291–300.
4. Andes D et al. Antimicrob Agents Chemother 2018;62(7).
5. Desai AV et al. Antimicrob Agents Chemother 2017;61(12).
6. Kovanda LL et al. Antimicrob Agents Chemother 2017;61(6).
7. VFEND GB Summary of Product Characteristics.
8. Noxafil Summary of Product Characteristics.
9. Sporanox Summary of Product Characteristics.
10. Imbruvica Summary of Product Characteristics.
11. Cummins KC et al. Leuk Lymphoma 2019;60(2):527–530.
How does the safety profile of CRESEMBA® impact my patients? Find out more LoadingDownload the CRESEMBA® dosing guide DownloadLoading
PP-CRB-GBR-1781. March 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​